AMARIN CORP PLC\UK Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
AMARIN CORP PLC\UK (AMRN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $400.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-02
- AMARIN CORP PLC\UK share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $400.00K.
- AMARIN CORP PLC\UK share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $4.90M, a 45.56% decline from fiscal 2020.
- AMARIN CORP PLC\UK share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $9.00M, a 90.06% decline from fiscal 2019.
- AMARIN CORP PLC\UK share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2019 was $90.50M, a 29.84% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2023-12-31 | $400.00K 10-K · filed 2026-03-02 |
| 2021-12-31 | $4.90M 10-K · filed 2024-02-29 |
| 2020-12-31 | $9.00M 10-K · filed 2023-03-01 |
| 2019-12-31 | $90.50M 10-K · filed 2022-03-01 |
| 2018-12-31 | $69.70M 10-K · filed 2021-02-25 |
| 2017-12-31 | $500.00K 10-K · filed 2020-02-25 |
| 2016-12-31 | $200.00K 10-K · filed 2019-02-27 |
| 2015-12-31 | $6.00K 10-K · filed 2018-02-27 |
| 2014-12-31 | $200.00K 10-K · filed 2017-03-01 |
| 2013-12-31 | $2.40M 10-K · filed 2015-03-03 |
| 2012-12-31 | $34.10M 10-K · filed 2014-02-27 |
| 2011-12-31 | $11.90M 10-K · filed 2013-02-28 |
| 2010-12-31 | $10.30M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |